FTSV Forty Seven Inc.

14.44
+0.3  (+2%)
Previous Close 14.14
Open 14.25
Price To Book 3.85
Market Cap 610,467,317
Shares 42,276,130
Volume 463,184
Short Ratio
Av. Daily Volume 218,946
Stock charts supplied by TradingView

NewsSee all news

  1. Forty Seven, Inc. Reports Third Quarter 2019 Financial Results and Recent Business Highlights

    -- On-Track to Initiate Potential Registration-Enabling Trials in MDS and DLBCL in 1Q 2020 ---- Entered into Collaboration with bluebird bio to Evaluate Antibody-Based Conditioning Regimen in Combination with LentiGlobin

  2. bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy

    bluebird bio, Inc. (NASDAQ:BLUE) and Forty Seven, Inc. (NASDAQ:FTSV) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven's novel antibody-based

  3. Forty Seven, Inc. to Present New Clinical and Preclinical Data on Magrolimab and FSI-174 at 61st ASH Annual Meeting

    MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer,

  4. Forty Seven Inc. to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

    MENLO PARK, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today

  5. Forty Seven Inc. to Present at 2019 Cantor Global Healthcare Conference

    MENLO PARK, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Registration-enabling trial to be initiated 1Q 2020 with interim data due 4Q 2020.
5F9 + rituximab
Non-Hodgkin Lymphoma (NHL) - cancer
Phase 1b/2 data due 4Q 2019.
5F9 + cetuximab
Colorectal cancer
Phase 1b data at ASCO June 3, 2019 noted 10% ORR.
5F9
Acute myeloid leukemia (AML)
Phase 1b presentation at ASH December 9, 2019, 8:00 a.m EST.
5F9 + Azacitidine
Acute myeloid leukemia (AML)
Phase 1 trial ongoing.
5F9
Solid tumors
Phase 1b data due 1Q 2020.
5F9 + Avelumab
Ovarian cancer

Latest News

  1. Forty Seven, Inc. Reports Third Quarter 2019 Financial Results and Recent Business Highlights

    -- On-Track to Initiate Potential Registration-Enabling Trials in MDS and DLBCL in 1Q 2020 ---- Entered into Collaboration with bluebird bio to Evaluate Antibody-Based Conditioning Regimen in Combination with LentiGlobin

  2. bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy

    bluebird bio, Inc. (NASDAQ:BLUE) and Forty Seven, Inc. (NASDAQ:FTSV) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven's novel antibody-based

  3. Forty Seven, Inc. to Present New Clinical and Preclinical Data on Magrolimab and FSI-174 at 61st ASH Annual Meeting

    MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer,

  4. Forty Seven Inc. to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

    MENLO PARK, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today

  5. Forty Seven Inc. to Present at 2019 Cantor Global Healthcare Conference

    MENLO PARK, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer,

  6. Forty Seven Inc. to Present at Morgan Stanley 17th Annual Global Healthcare Conference

    MENLO PARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer,

  7. Forty Seven, Inc. Granted Fast Track Designation for Magrolimab (5F9) for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia

    MENLO PARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced